However, coadministration of LL-KF140 resulted in a 27% lower CML level than that in the CLRP alone treatment group 24 h post-administration (p < 0.05; Figure 2A). This evidence concerns the gene NYX and chronic myelogenous leukemia, BCR-ABL1 positive.